![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
September 30, 2021
A new Language Guide provides guidelines on best practices with common phrases to use during presentations at medical conferences and within submitted abstracts
September 30, 2021
The ethical imperative is that we must not treat the patient as a mere subject but as a participant partner, who therefore has rights to information about the trial to which they contributed
September 30, 2021
This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
September 30, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 23, 2021
Fall 2021 Group Meeting to be virtual; a new prevention trial; the case for COVID-19 vaccination
August 17, 2021
This phase II study is testing the effects and safety of green tea catechins (GTC) as a chemopreventive agent
August 17, 2021
This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
August 17, 2021
This study is evaluating two different screening strategies for non-cancerous pancreatic cysts; recently activated amendment #2 expands the eligibility criteria
August 17, 2021
This phase II trial is comparing adjuvant treatment with either reirradiation plus pembrolizumab, pembrolizumab monotherapy, or reirradiation with platinum chemotherapy
August 17, 2021
A Standing Main Member of ECOG-ACRIN since 1972
August 17, 2021
July 7, 2021
ECOG-ACRIN will hold its Fall 2021 Group Meeting as a face-to-face meeting for the first time in two years